Trials / Available
AvailableNCT05593185
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Sellas Life Sciences Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Galinpepimut-S |
Timeline
- First posted
- 2022-10-25
- Last updated
- 2024-12-09
Source: ClinicalTrials.gov record NCT05593185. Inclusion in this directory is not an endorsement.